This information is for
Patients & Caregivers

Safety First

Roll over to read about possible side effects ›

Important Safety Information

  • PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure)
  • Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects
    • If you think you may be pregnant, you should contact your healthcare provider immediately
    • If you are exposed to PERJETA during pregnancy, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720
  • PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA
  • Other possible side effects of PERJETA therapy include:
    • Infusion-related reactions
    • Severe allergic reactions (hypersensitivity reactions/anaphylaxis)
  • PERJETA has only been shown to work in people with HER2-positive breast cancer
  • The most common side effects of PERJETA when given with Herceptin and docetaxel (chemotherapy) for treatment of breast cancer that has spread to other parts of the body (metastatic) are:
    • Diarrhea
    • Hair loss
    • Low levels of white blood cells with or without a fever
    • Nausea
    • Feeling tired
    • Rash
    • Damage to the nerves (numbness, tingling, pain in hands/feet)

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see PERJETA full Prescribing Information, including Most Serious Side Effects, for additional Important Safety Information.

PERJETA Support Line
Talk to a nurse anytime.
Call the PERJETA Support Line:
1 (855) PERJETA, or 1 (855) (737-5382).

The information you receive from the PERJETA Support Line is not meant to replace the advice of your healthcare team.

PERJETA Access Solutions

Genentech can help you with financial support and insurance issues.

Click here to see how we can help you >

The Access Solutions logo is a registered trademark of Genentech, Inc.

Genentech BioOncology™
Co-pay Card

Helps eligible patients with their insurance co-payments for PERJETA.

Learn more >

Genentech® Access to Care Foundation (GATCF)

Helps eligible patients who don’t have a healthcare plan pay for PERJETA.

Learn more >

1
2
3

What does PERJETA treat?

PERJETA® (pertuzumab) is approved for use in combination with Herceptin® (trastuzumab) and docetaxel in people with HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.

PERJETA® (pertuzumab) is approved for use prior to surgery in combination with Herceptin® (trastuzumab) and docetaxel in people with HER2-positive, locally advanced, inflammatory, or early stage (tumor is greater than 2 cm in diameter or node positive) breast cancer. PERJETA is used as part of a complete treatment regimen for early stage breast cancer. This use of PERJETA is based on an improvement in the percentage of patients whose cancer shrinks or disappears after treatment. Currently, no data have shown whether or not treatment with PERJETA prior to surgery improves survival. The safety of PERJETA in combination with doxorubicin-containing regimens has not been established. The safety of PERJETA administered for greater than 6 cycles for early breast cancer has not been established.

What should I know about side effects with PERJETA?

  • Not all people have serious side effects; however, side effects with PERJETA therapy are common. It is important to know what side effects may happen and what symptoms you should watch for
  • Your doctor may stop treatment if serious side effects happen. Be sure to contact your healthcare team right away if you have questions or are worried about any side effects

What are the most serious side effects?

Most Serious Side Effects:
  • PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).

  • Your doctor may run tests to monitor your heart function before and during treatment with PERJETA
 

Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects.

  • Birth control should be used while receiving PERJETA and for 6 months after your last dose of PERJETA. If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or stopping PERJETA
  • If you think you may be pregnant, you should contact your healthcare provider immediately
  • If you are exposed to PERJETA during pregnancy, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting
    1-800-690-6720

What are other possible serious side effects?

  • PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA
  • Infusion-related reactions: PERJETA is a medicine that is delivered into a vein through a needle. This process can cause reactions known as infusion-related reactions. The most common infusion-related reactions when receiving PERJETA, Herceptin, and docetaxel were feeling tired, abnormal or altered taste, allergic reactions, muscle pain, and vomiting
  • Severe allergic reactions: Some people receiving PERJETA may have severe allergic reactions, called hypersensitivity reactions or anaphylaxis. This reaction may be severe, may happen quickly, and may affect many areas of the body

How will my doctor and I know if PERJETA is right for me?

PERJETA has been shown to work only in people with HER2-positive breast cancer. You must have a HER2 test to know if your breast cancer is HER2-positive before receiving an anti-HER2 treatment, such as PERJETA.

What are the most common side effects?

The most common side effects of PERJETA when given with Herceptin and docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are:

  • Diarrhea
  • Hair loss
  • Low levels of white blood cells with or without a fever
  • Nausea
  • Feeling tired
  • Rash
  • Damage to the nerves (numbness, tingling, pain in hands/feet)

The most common side effects of PERJETA when given with Herceptin and docetaxel as part of an early breast cancer regimen before surgery are:

  • Hair loss
  • Diarrhea
  • Nausea
  • Low levels of white blood cells with or without a fever

The most common side effects of PERJETA when given with Herceptin and docetaxel following 3 cycles of epirubicin, cyclophosphamide, and fluorouracil as part of an early breast cancer regimen before surgery are:

  • Feeling tired
  • Hair loss
  • Diarrhea
  • Nausea
  • Vomiting
  • Low levels of white blood cells with or without a fever

The most common side effects of PERJETA when given with Herceptin, docetaxel, and carboplatin as part of an early breast cancer regimen before surgery are:

  • Feeling tired
  • Hair loss
  • Diarrhea
  • Nausea
  • Vomiting
  • Low levels of white blood cells with or without a fever
  • Low platelet count
  • Low levels of red blood cells

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see PERJETA full Prescribing Information including Most Serious Side Effects for additional Important Safety Information.

For 24-hour support, call 1 (855) PERJETA (737-5382)

Third-Party Website Disclaimer


The link you selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech is not part of the site, nor does it control the content. Genentech does not guarantee the information on the page. Your use of third-party websites is at your own risk and is subject to the third-party website’s privacy policy and terms and conditions for use of such sites.

  • OK
  • Close

http://www.perjeta.com

The information contained in this section of the site is intended for US Healthcare professionals only. Select "OK" if you are a US healthcare professional.

  • OK
  • Close